Literature DB >> 2584706

Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.

Y Morinaga1, H Suzuki, F Takatsuki, Y Akiyama, T Taniyama, K Matsushima, K Onozaki.   

Abstract

The role of IL-6 in the antiproliferative effect of IL-1 for tumor cell lines was investigated using IL-1-sensitive cell lines. Human recombinant IL-1 alpha and IL-6 both inhibited the growth of an IL-1-sensitive cloned human melanoma cell line (A375-C6). However, IL-1 has greater maximum growth inhibitory activity than IL-6. Conditioned medium of the tumor cells that were treated with IL-1 contained IL-6 as determined by ELISA. Northern blot analysis revealed that IL-6 mRNA expression increased in IL-1-treated cells. In addition, antibody against human IL-6 neutralized about 50% of the antiproliferative effect of IL-1. The growth of an IL-1-resistant clone of A375 cells (A375-C5), which cannot be shown to express any detectable IL-1R, was inhibited by IL-6 to the same degree as A375-C6 cells. The A375-C5 cell line did not produce IL-6 or increase IL-6 mRNA after stimulation with IL-1. These results indicate that IL-6 mediates in part the antiproliferative effect of IL-1 on A375-C6 cells by acting as an autocrine antiproliferative factor. IL-1 also inhibited the growth of a malignant human mammary cell line (MDA-MB-415). IL-6 exhibited only slight growth inhibition in this cell line. Neither IL-6 production nor IL-6 mRNA expression was induced in this cell line by IL-1. Antibody against IL-6 did not neutralize the antiproliferative effect of IL-1. Therefore, for MDA-MB-415 cells IL-6 appeared not to be involved in the antiproliferative effect of IL-1. These results indicate that the antiproliferative effect of IL-1 involves at least two pathways, one IL-6 dependent and another IL-6 independent. The contribution of IL-6 to the antiproliferative effect of TNF was also examined. IL-6 appeared not to play a role in the antiproliferative effect of TNF in these cell lines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584706

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer.

Authors:  Ewa Jablonska; Leszek Piotrowski; Zyta Grabowska
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 2.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

3.  The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest.

Authors:  S F Sells; S Muthukumar; V P Sukhatme; S A Crist; V M Rangnekar
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

4.  An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer.

Authors:  Junji Itou; Sunao Tanaka; Fumiaki Sato; Ryutaro Akiyama; Yasuhiko Kawakami; Masakazu Toi
Journal:  Biochim Biophys Acta       Date:  2014-10-12

5.  Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.

Authors:  M Kawada; M Ishizuka; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1999-05

Review 6.  GP130 Cytokines in Breast Cancer and Bone.

Authors:  Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancers (Basel)       Date:  2020-01-31       Impact factor: 6.639

7.  IL-1beta acts in synergy with endogenous IL-1beta in A375-S2 human melanoma cell apoptosis through mitochondrial pathway.

Authors:  Che Wang; Min-wei Wang; Shin-ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

8.  Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; M Boddi; E Gallina; O Fini; R Abbate
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.